While clec7a over-expression conferred a prior drug resistance in leukemic cells 40, 41 and was prognostic of poor prostate cancer relapse-free survival 42, it constituted as one member of the immune-related prognostic panel associated with favorable melanoma survival 43 whose mutation has been associated with immunodeficiency and the pathogenesis of retinoblastoma 44. This evidence concerns the gene CLEC7A and prostate cancer.